Synopsis:
Pharma stock surged 6% after strong Q1FY26 results, with a 49% YoY rise in net profit and 7% revenue growth. Robust EBITDA margin, global expansion, multiple product launches, and an advancing development pipeline reinforced investor confidence and growth potential.
The shares of the pharmaceutical company gained up to 6 percent in today’s trading session after the company’s net profit and revenue surged 49 percent and 7 percent, respectively, in Q1FY26.
With a market capitalization of Rs 32,719.80 crore, the shares of Gland Pharma Ltd were trading at Rs 1,985.00 per share, increasing around 1.55 percent as compared to the previous closing price of Rs 1,964.45 apiece.
The shares of Gland Pharma Ltd have seen positive movement after reporting positive results in Q1FY26. Revenue increased by 6 percent on a quarter-on-quarter basis from Rs. 1,425 crore in Q4FY25 to Rs. 1,506 crore in Q1FY26. Further, revenue increased by 7 percent year on year, from Rs 1,402 crore in Q1FY25 to Rs 1,506 crore in Q1FY26.
The company’s net profit increased by 15 percent on a quarter-on-quarter basis, from Rs.187 crore in Q4FY25 to Rs. 215 crore in Q1FY26. Further, net profit increased significantly by 49 percent year on year from Rs 144 crore in Q1FY25 to Rs 215 crore in Q1FY26.
Additionally, EBITDA surged 39% year-on-year to ₹368 crore in Q1FY26, up from ₹264.5 crore last year, with margins expanding significantly to 24.4% from 19%, reflecting strong operational efficiency.
Gland Pharma reported Rs 460 million in R&D expenses for Q1 FY26, launching 12 new molecules and securing nine ANDA approvals. It continues expanding its complex injectable pipeline and co-development partnerships. The company scaled GLP-1/Pen/cartridge capacity and launched services in new markets. It also received a GMP compliance Certificate from the Danish Medicines Agency for aseptically prepared Powder.
Gland Pharma is advancing 15 co-developed products, seven via the 505(b)(2) route and eight as ANDAs, with commercialization set for FY28. It also filed one more RTU infusion bag in Q1 FY26, taking the U.S. total to 20 filings and 14 approvals. Ten additional RTU products are in development, addressing a sizable $767 million market opportunity.
In Q1 FY26, Gland Pharma saw mixed regional performances. The US market dipped 2% YoY, while Europe rose 29% led by strong launches and tech transfers. The company launched several new molecules, contributing to growth across Cenexi and Gland entities. Europe contributed 22% to the group’s revenue, highlighting its growing strategic importance.
Other Core Markets grew 65% YoY, driven by a successful Australia launch of GLP-1. India and RoW segments posted 13% and 5% YoY growth, respectively, led by volume upticks in key products. Overall, diversified global expansion and strong product launches fueled a resilient performance amid regional variances.
Gland Pharma Limited specializes in complex injectables and is engaged in the sterile injectables, oncology, and ophthalmology segments. The Company provides contract development, own development, dossier preparation and filing, technology transfer, and manufacturing across a variety of delivery systems.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
